Savara shares surge 10.15% intraday after European patent approval for Molbreevi drug-device combo strengthens IP protection.

Savara (SVRA) surged 10.15% intraday following the announcement that it and PARI secured a European patent for the drug-device combination of MOLBREEVI and the eFlow® Nebulizer System, extending IP protection through 2043. The patent, coupled with 10 years of orphan drug exclusivity upon EU approval, strengthens MOLBREEVI’s commercial prospects for treating autoimmune PAP. The news coincides with management’s upcoming high-profile healthcare conferences and planned regulatory submissions, including a December U.S. BLA resubmission and Q1 2026 European MAA filings, amplifying investor optimism. The stock’s sharp intraday rally aligns with renewed focus on its rare disease pipeline and intellectual property milestones, despite a high price-to-book ratio of 14.9x. The patent approval and near-term regulatory catalysts directly underpin the bullish move.